Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Insight Molecular Diagnostics (IMDX) Return on Capital Employed (2020 - 2025)

Insight Molecular Diagnostics (IMDX) has disclosed Return on Capital Employed for 6 consecutive years, with 0.46% as the latest value for Q4 2025.

  • Quarterly Return on Capital Employed rose 88.0% to 0.46% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.46% through Dec 2025, up 88.0% year-over-year, with the annual reading at 0.57% for FY2025, 70.0% up from the prior year.
  • Return on Capital Employed hit 0.46% in Q4 2025 for Insight Molecular Diagnostics, up from 1.55% in the prior quarter.
  • In the past five years, Return on Capital Employed ranged from a high of 0.11% in Q1 2023 to a low of 1.55% in Q3 2025.
  • Historically, Return on Capital Employed has averaged 0.59% across 5 years, with a median of 0.43% in 2021.
  • Biggest five-year swings in Return on Capital Employed: plummeted -99bps in 2024 and later surged 88bps in 2025.
  • Year by year, Return on Capital Employed stood at 0.5% in 2021, then skyrocketed by 69bps to 0.15% in 2022, then tumbled by -129bps to 0.35% in 2023, then tumbled by -280bps to 1.35% in 2024, then skyrocketed by 66bps to 0.46% in 2025.
  • Business Quant data shows Return on Capital Employed for IMDX at 0.46% in Q4 2025, 1.55% in Q3 2025, and 1.31% in Q2 2025.